[Disclosure] Alteogen (196170) Postpones Subsidiary Merger Schedule; Final Merger Date Amended to December 31

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-11-14

Disclosure Type: Decision on Corporate Merger (Major Management Matters of a Subsidiary) (Amendment)

💡 3-Second Summary

Alteogen has revised its subsidiary restructuring timeline, shifting the final merger date between Altos Biologics and Alteogen Healthcare from December 24 to December 31, 2024.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Amendments (Timeline Postponement):
  • General Meeting of Shareholders: Delayed from November 22, 2024 $\rightarrow$ To November 29, 2024
  • Creditor Objection Period: Delayed from Nov 23 – Dec 23, 2024 $\rightarrow$ To Nov 30 – Dec 30, 2024
  • Merger Date (Effective Date): Delayed from December 24, 2024 $\rightarrow$ To December 31, 2024
  • Expected Registration Date: Delayed from December 30, 2024 $\rightarrow$ To January 7, 2025
  • Board Resolution Date: Adjusted from November 7, 2024 $\rightarrow$ To November 14, 2024
• Merger Methodology: Absorption merger where Altos Biologics, Inc. (Surviving Entity) absorbs Alteogen Healthcare, Co., Ltd. (Dissolving Entity) to improve management efficiency.
• Merger Ratio & Share Distribution:
  • Merger Ratio: Altos Biologics : Alteogen Healthcare = 1.0000000 : 0.2741924
  • New Merger Shares to be Issued: 1,390,130 Common Shares and 277,970 Preferred Shares
• Subsidiary Financial Asset Profile:
  • Surviving Subsidiary: Altos Biologics, Inc. (Asset size at KRW 63,593,090,629 / Approx. KRW 63.6B)
  • Asset Weight Against Parent Consolidated Assets: 24.83% (Classified as a major subsidiary)
• Appraisal Rights: Pursuant to Article 522-3 of the Commercial Act, dissenting shareholders who notify the company of their opposition prior to the shareholder meeting (November 29) may exercise their appraisal rights within 20 days from the resolution date.

📈 2. [Expert View: What This Disclosure Means for Investors]

• Fine-Tuning of Corporate Restructuring Timeline: An adjustment in the execution schedule and board resolution timelines made one week after the initial announcement pushed the final execution date to the last day of the year (December 31). This update represents a minor technical timeline calibration to coordinate legal processes rather than any structural alteration in management’s underlying integration metrics or valuation ratios.
• No Material Impact on Consolidated Financials: Because this transaction is an internal rebalancing between two wholly owned subsidiaries under the same corporate umbrella, it does not involve external capital allocation. The filing indicates a routine administrative change that carries no material exposure regarding consolidated assets or liabilities.
• Investor Caution: This filing serves as an amendment outlining changes to the transaction timeline of a major subsidiary that accounts for 24.83% of consolidated assets. Investors should monitor the rescheduled shareholder meeting on November 29 and check if the subsequent creditor objection windows close without unexpected administrative friction.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s internal corporate consolidation schedule, involving the merger between Altos Biologics and Alteogen Healthcare, has been shifted slightly by one week, anchoring the final integration to the last day of the fiscal year, December 31. This timeline calibration appears designed to align the corporate effective date with year-end accounting reporting boundaries. Since this remains a non-cash structural adjustment between existing sister subsidiaries, it creates zero liquidity outflow and carries no immediate pressure on parent-level trading parameters. Long-term market participants should simply observe whether the newly structured corporate governance rails lock in cleanly through the updated November 29 voting deadline.

📢 Disclaimer & Source Information

Source: This content was structured and newly written based on the official submitted data from the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.